Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Adjuvant sequential chemoradiation therapy in high-risk endometrial cancer: results of a prospective, multicenter phase-II study of the NOGGO (North-Eastern German Society of Gynaecological Oncology).

Mustea A, Koensgen D, Belau A, Sehouli J, Lichtenegger W, Schneidewind L, Sommer H, Markmann S, Scharf JP, Ehmke M, Ledwon P, Braicu I, Zygmunt M, Koehler G.

Cancer Chemother Pharmacol. 2013 Nov;72(5):975-83. doi: 10.1007/s00280-013-2276-9. Epub 2013 Sep 1.

PMID:
23995698
2.

Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.

de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Kitchener HC, Nijman HW, Kruitwagen RF, Nout RA, Verhoeven-Adema KW, Smit VT, Putter H, Creutzberg CL; PORTEC study group.

Lancet Oncol. 2016 Aug;17(8):1114-1126. doi: 10.1016/S1470-2045(16)30120-6. Epub 2016 Jul 7.

3.

Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.

Rao GG, Rogers P, Drake RD, Nguyen P, Coleman RL.

Gynecol Oncol. 2005 Jan;96(1):168-72.

PMID:
15589596
4.

Adjuvant paclitaxel and carboplatin chemotherapy with involved field radiation in advanced endometrial cancer: a sequential approach.

Lupe K, Kwon J, D'Souza D, Gawlik C, Stitt L, Whiston F, Nascu P, Wong E, Carey MS.

Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):110-6. Epub 2006 Nov 2.

PMID:
17084542
6.

A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer.

Duska LR, Berkowitz R, Matulonis U, Muto M, Goodman A, McIntyre JF, Klein A, Atkinson T, Seiden MV, Campos S.

Gynecol Oncol. 2005 Jan;96(1):198-203.

PMID:
15589601
7.

Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer.

Kiess AP, Damast S, Makker V, Kollmeier MA, Gardner GJ, Aghajanian C, Abu-Rustum NR, Barakat RR, Alektiar KM.

Gynecol Oncol. 2012 Nov;127(2):321-5. doi: 10.1016/j.ygyno.2012.07.112. Epub 2012 Jul 28.

PMID:
22850412
8.

Concomitant radiotherapy and paclitaxel for high-risk endometrial cancer: first feasibility study.

Frigerio L, Mangili G, Aletti G, Carnelli M, Garavaglia E, Beatrice S, Ferrari A.

Gynecol Oncol. 2001 Apr;81(1):53-7.

PMID:
11277649
9.

Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors.

Landrum LM, Nugent EK, Zuna RE, Syzek E, Mannel RS, Moore KN, Walker JL, McMeekin DS.

Gynecol Oncol. 2014 Jan;132(1):50-4. doi: 10.1016/j.ygyno.2013.11.005. Epub 2013 Nov 9.

PMID:
24219982
10.

Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancer.

Milgrom SA, Kollmeier MA, Abu-Rustum NR, Tew WP, Sonoda Y, Barakat RR, Alektiar KM.

Gynecol Oncol. 2013 Sep;130(3):436-40. doi: 10.1016/j.ygyno.2013.06.024. Epub 2013 Jun 22.

PMID:
23800696
11.
12.

Concomitant paclitaxel plus carboplatin and radiotherapy for high-risk or advanced endometrial cancer.

Wen Q, Shao Z, Yang Z.

Int J Gynecol Cancer. 2013 May;23(4):685-9. doi: 10.1097/IGC.0b013e3182808232.

PMID:
23615571
13.
14.

Sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: results of a multicenter phase II study of the northeastern German society of gynecological oncology.

Oskay-Ozcelik G, Chekerov R, Sommer H, Keil E, Einenkel J, Pfisterer J, Lorenz-Schlüter C, Lichtenegger W, Camara O, Sehouli J.

Gynecol Oncol. 2010 Mar;116(3):317-22. doi: 10.1016/j.ygyno.2009.09.031. Epub 2009 Dec 2.

PMID:
19959213
15.

Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer.

Greven K, Winter K, Underhill K, Fontenesci J, Cooper J, Burke T; Radiation Therapy Oncology Group.

Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):168-73.

PMID:
15093913
16.

Sequential versus "sandwich" sequencing of adjuvant chemoradiation for the treatment of stage III uterine endometrioid adenocarcinoma.

Lu SM, Chang-Halpenny C, Hwang-Graziano J.

Gynecol Oncol. 2015 Apr;137(1):28-33. doi: 10.1016/j.ygyno.2015.01.546. Epub 2015 Feb 7.

PMID:
25666606
17.

Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712.

Davies AM, Chansky K, Lau DH, Leigh BR, Gaspar LE, Weiss GR, Wozniak AJ, Crowley JJ, Gandara DR; SWOG S9712.

J Clin Oncol. 2006 Nov 20;24(33):5242-6.

PMID:
17114656
18.

Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.

Pallarés C, Capdevila J, Paredes A, Farré N, Ciria JP, Membrive I, Basterrechea L, Gomez-Segura G, Barnadas A.

Lung Cancer. 2007 Nov;58(2):238-45. Epub 2007 Jul 20.

PMID:
17658655
19.

A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium.

Jhingran A, Ramondetta LM, Bodurka DC, Slomovitz BM, Brown J, Levy LB, Garcia ME, Eifel PJ, Lu KH, Burke TW.

Gynecol Oncol. 2013 May;129(2):304-9. doi: 10.1016/j.ygyno.2013.01.025. Epub 2013 Feb 4.

20.

A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer.

Geller MA, Ivy JJ, Ghebre R, Downs LS Jr, Judson PL, Carson LF, Jonson AL, Dusenbery K, Vogel RI, Boente MP, Argenta PA.

Gynecol Oncol. 2011 Apr;121(1):112-7. doi: 10.1016/j.ygyno.2010.12.338. Epub 2011 Jan 15.

PMID:
21239048

Supplemental Content

Support Center